Pregnancy and infant outcomes following SARS-CoV-2 infection in pregnancy during delta variant predominance – Surveillance for Emerging Threats to Pregnant People and Infants

Prenatal Maternal Immunization for Infant Protection: A Review of the Vaccines Recommended, Infant Immunity and Future Research Directions

“…They are also more susceptible to adverse pregnancy and neonatal outcomes compared to pregnant women without COVID-19 such as stillbirth (OR 1.81, 95% CI, 1.38–2.37), preterm birth (OR 1.57, 95% CI, 1.36–1.81), and their infant’s needing admission to neonatal intensive care (OR 2.18, 95% CI, 1.46–3.26) [ 11 ]. These adverse outcomes were further exemplified during the Delta period with an increase in stillbirths (0.7% versus 0.4%, adjusted prevalence ratio (aPR) 1.55, 95% CI 1.14–2.09) and preterm births (12.8% versus 11.9%, aPR 1.14, 95% CI 1.07–1.20) compared to the pre-Delta period [ 131 ]. While pregnant women were excluded from pre-licensure vaccine clinical trials, they were offered the opportunity to receive the vaccine during the initial rollout of COVID-19 vaccination in December 2020 [ 69 ].…”